rs2282679 Genotype/Allele | Disease-Free Survival | P interaction c | Overall Survival | P interaction c | ||
---|---|---|---|---|---|---|
No. of Eventsa /At Risk | HR (95% CI)b | No. of Eventsa /At Risk | HR (95% CI)b | |||
Total colorectal cancer | Â | Â | Â | Â | Â | Â |
 AA | 83/245 | 1.00 |  | 69/245 | 1.00 |  |
 AC | 80/207 | 1.33 (0.94–1.88) |  | 68/208 | 1.24 (0.85–1.81) |  |
 CC | 16/36 | 1.93 (1.06–3.52) |  | 13/36 | 1.60 (0.85–3.02) |  |
 P trendd |  | 0.020 |  |  | 0.107 |  |
 CC + AC (vs. AA) | 96/243 | 1.40 (1.00–1.95) |  | 81/244 | 1.29 (0.90–1.85) |  |
 CC (vs. AC + AA) | 16/36 | 1.69 (0.95–2.99) |  | 13/36 | 1.44 (0.79–2.65) |  |
 Per C allele |  | 1.36 (1.05–1.77) |  |  | 1.26 (0.95–1.66) |  |
BRAF Val600Glu mutant | Â | Â | Â | Â | Â | Â |
 AA | 8/20 | 1.00 |  | 5/20 | 1.00 |  |
 CC + ACe | 8/26 | 0.95 (0.25–3.62) |  | 7/26 | 1.53 (0.47–4.95) |  |
BRAF wild-type | Â | Â | Â | Â | Â | Â |
 AA | 65/200 | 1.00 |  | 55/200 | 1.00 |  |
 CC + AC e | 83/195 | 1.58 (1.12–2.23) | 0.043 | 70/196 | 1.33 (0.93–1.91) | 0.892 |
MSI-H | Â | Â | Â | Â | Â | Â |
 AA | 3/25 | 1.00 |  | 0/26 | 1.00 |  |
 CC + ACe | 5/28 | 1.26 (0.18–8.96) |  | 3/28 | NCf |  |
MSS/MSI-L | Â | Â | Â | Â | Â | Â |
 AA | 76/204 | 1.00 |  | 65/204 | 1.00 |  |
 CC + ACe | 87/203 | 1.34 (0.97–1.87) | 0.702 | 74/204 | 1.26 (0.89–1.77) | 0.210 |